Temporal stability of fecal metabolomic profiles in irritable bowel syndrome

被引:0
|
作者
Iribarren, Cristina [1 ]
Savolainen, Otto [2 ,3 ]
Sapnara, Maria [1 ]
Toernblom, Hans [4 ]
Simren, Magnus [4 ,5 ]
Magnusson, Maria K. [1 ]
Ohman, Lena [1 ,6 ]
机构
[1] Univ Gothenburg, Inst Biomed, Sahlgrenska Acad, Dept Microbiol & Immunol, Gothenburg, Sweden
[2] Chalmers Univ Technol, Dept Biol & Biol Engn, Chalmers Mass Spectrometry Infrastruct, Gothenburg, Sweden
[3] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland
[4] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden
[5] Univ N Carolina, Ctr Funct Gastrointestinal & Motil Disorders, Chapel Hill, NC USA
[6] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Box 435, S-40530 Gothenburg, Sweden
来源
NEUROGASTROENTEROLOGY AND MOTILITY | 2024年 / 36卷 / 03期
基金
瑞典研究理事会;
关键词
fecal metabolites; irritable bowel syndrome; longitudinal; metabolomics; temporal dynamic; MICROBIOTA; CONSISTENCY; SEVERITY; SAMPLES; IBS;
D O I
10.1111/nmo.14741
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe potential of the fecal metabolome to serve as a biomarker for irritable bowel syndrome (IBS) depends on its stability over time. Therefore, this study aimed to determine the temporal dynamics of the fecal metabolome, and the potential relationship with stool consistency, in patients with IBS and healthy subjects.MethodsFecal samples were collected in two cohorts comprising patients with IBS and healthy subjects. For Cohort A, fecal samples collected during 5 consecutive days were analyzed by gas chromatography-tandem mass spectrometry (GC-MS/MS). For Cohort B, liquid chromatography-MS (LC-MS) was used to analyze fecal samples collected at week 0 (healthy and IBS) and at week 4 (patients only). Stool consistency was determined by the Bristol Stool Form scale.Key ResultsFecal samples were collected from Cohort A (seven healthy subjects and eight IBS patients), and Cohort B (seven healthy subjects and 11 IBS patients). The fecal metabolome of IBS patients was stable short-term (Cohort A, 5 days and within the same day) and long-term (Cohort B, 4 weeks). A similar trend was observed over 5 days in the healthy subjects of Cohort A. The metabolome dissimilarity was larger between than within participants over time in both healthy subjects and IBS patients. Further analyses showed that patients had greater range of stool forms (types) than healthy subjects, with no apparent influence on metabolomic dynamics.Conclusion & InferencesThe fecal metabolome is stable over time within IBS patients as well as healthy subjects. This supports the concept of a stable fecal metabolome in IBS despite fluctuations in stool consistency, and the use of single timepoint sampling to further explore how the fecal metabolome is related to IBS pathogenesis. The metabolite profile of fecal samples remains stable over time in IBS and health, independently of stool consistency fluctuations. Single timepoint sampling might be used to further explore how the fecal metabolome is related to IBS pathogenesis.image
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Metabolomic and microbial profiles identify subsets of diarrhea predominant irritable bowel syndrome
    Bennet, Sean M. P.
    De Palma, Giada
    Bercik, Premysl
    Lomax, Alan E.
    Vanner, Stephen J.
    Reed, David E.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [2] Fecal fat excretion in irritable bowel syndrome
    Berstad, Arnold
    Morken, Mette Helvik
    Lied, Gulen Arslan
    Lind, Ragna
    Hjartholm, Aud-Sissel
    Valeur, Jorgen
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (8-9) : 1120 - 1121
  • [3] Impact of fecal incontinence on irritable bowel syndrome
    Palsson, Olafur S.
    Ringel, Yehuda
    Van tilburg, Miranda A.
    Gangarosa, Lisa M.
    Turner, Marsha
    Kanazawa, Motoyori
    Thiwan, Syed ismail M.
    Drossman, Douglas A.
    Whitehead, William E.
    GASTROENTEROLOGY, 2007, 132 (04) : A678 - A678
  • [4] Fecal incontinence in patients with irritable bowel syndrome
    Jerlstad, Pernilla
    Jerndal, Per
    Karpefors, Martin
    Bayati, Alfred
    Ringstrom, Gisela
    Agerforz, Pia
    Abrahamsson, Hasse
    Simren, Magnus
    GASTROENTEROLOGY, 2008, 134 (04) : A278 - A278
  • [5] The fecal mycobiome in patients with Irritable Bowel Syndrome
    Das, A.
    O'Herlihy, E.
    Shanahan, F.
    O'Toole, P. W.
    Jeffery, I. B.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] The fecal mycobiome in patients with Irritable Bowel Syndrome
    A. Das
    E. O’Herlihy
    F. Shanahan
    P. W. O’Toole
    I. B. Jeffery
    Scientific Reports, 11
  • [7] Irritable Bowel Syndrome: what is the benefit of Fecal Transplantation?
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07):
  • [8] FECAL MICROBIAL-FLORA IN THE IRRITABLE BOWEL SYNDROME
    GUSLANDI, M
    TITTOBELLO, A
    BALSARI, A
    FESCE, E
    GUT, 1981, 22 (05) : A441 - A441
  • [9] Fecal Microbiota Transplant Effective for Irritable Bowel Syndrome
    Ebell, Mark H.
    AMERICAN FAMILY PHYSICIAN, 2020, 102 (06) : 377 - 377
  • [10] THE FECAL MICROBIAL-POPULATION IN THE IRRITABLE BOWEL SYNDROME
    BALSARI, A
    CECCARELLI, A
    DUBINI, F
    FESCE, E
    POLI, G
    MICROBIOLOGICA, 1982, 5 (03): : 185 - 194